HKU Scholars Hub: Browsing DSpace

Browsing by Author Schluep, T

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 16 of 16

	Title	Author(s)	Issue Date	Views
	A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population Proceeding/Conference:Journal of Hepatology	Gane, E Schwabe, C Given, B Schluep, T Hamilton, J Lai, CL Locarnini, S Lau, J Ferrari, C Gish, R	2017	61
	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities Journal:Antiviral Research	Gish, RG Given, BD Lai, CL Locarnini, SA Lau, JYN Lewis, DL Schluep, T	2015	150
	Differential reductions in viral antigens expressed from cccDNAVS integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520 Proceeding/Conference:Journal of Hepatology	Yuen, RMF Chan, HLY Liu, K Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JYN Ferrari, C Gish, RG	2016	108
	Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB) Proceeding/Conference:Hepatology	Gane, EJ Locarnini, S Lim, TH Strasser, SI Sievert, W Cheng, W Thompson, A Given, BD Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2019	10
	Effective inhibition of cccDNA derived mRNA/viral antigens and tolerability with ARC-520 Proceeding/Conference:Hepatology International	Yuen, RMF Chan, HLY Liu, SHK Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JYN Ferrari, C Gish, RG	2016	83
	First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA) Proceeding/Conference:Hepatology	Yuen, RMF Locarnini, S Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Jackson, K Ferrari, C Lai, CL Liu, SHK Mak, LY Wong, DKH To, WP Ko, KL Gish, RG	2019	49
	First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV Proceeding/Conference:Hepatology	Gane, EJ Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Li, Z Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2018	55
	Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis Proceeding/Conference:Journal of Hepatology	Walsh, R Yuen, L Hammond, R Deerain, J Given, B Schluep, T Yuen, MF Chan, HLY Lai, CL Hamilton, J Lau, JY Ferrari, C Gish, RG Locarnini, SA	2016	91
	Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen Proceeding/Conference:Journal of Hepatology	Yuen, RMF Liu, SHK Chan, HLY Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JY Ferrari, C Gish, RG	2017	58
	RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV Proceeding/Conference:Journal of Hepatology	Yuen, RMF Liu, SHK Given, B Schluep, T Hamilton, J Lai, CL Locarnini, S Jackson, K Lai, JY Ferrari, C Gish, RG.	2018	73
	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg Journal:Science Translational Medicine	Wooddell, CI Yuen, RMF Chan, HLY Gish, RG Locarnini, SA Chavez, D Ferrari, C Given, BD Hamilton, J Kanner, SB Lai, CL Lai, JYN Schluep, T Xu, Z Lanford, RE Lewis, DL	2017	26
	Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers Journal:Clinical Pharmacology in Drug Development	Schluep, T Lickliter, J Hamilton, J Lewis, DL Lai, CL Lau, JYN Locarnini, SA Gish, RG Given, BD	2017	39
	Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold Proceeding/Conference:Journal of Hepatology	Yuen, RMF Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Gane, E	2019	47
	Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2020	32
	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent Journal:Antiviral Research	Gish, RG Yuen, RMF Chan, HLY Given, BD Lai, CL Locarnini, SA Lau, JYN Wooddell, CI Schluep, T Lewis, DL	2015	81
	Utility of a new HBV RNA assay in HBeAg positive and negative CHB and following HBsAg seroclearance in patients treated with ARC‐520, an RNAi drug targeting cccDNA derived HBV mRNA Proceeding/Conference:Journal of Viral Hepatitis	Buter, EK Wong, DKH Jackson, K Schluep, T Gersch, J Kuhns, M Cloherty, GA Locarnini, S Yuen, RMF	2018	30

Showing results 1 to 16 of 16